Posttreatment Hepatitis B Surface Antigen Seroreversion: The Bane of Combination Therapy in Chronic Hepatitis B?

Gastroenterology

Volumn 150, Issue 5, 2016, Pages 1254-1255

  Sonneveld, Milan J ^a   Brouwer, Willem P ^a   Van Der Meer, Adriaan J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; HEPATITIS B SURFACE ANTIGEN; TENOFOVIR; ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS B(E) ANTIGEN; RECOMBINANT PROTEIN; VIRUS DNA;

CHRONIC HEPATITIS B; FOLLOW UP; HUMAN; LETTER; MONOTHERAPY; PRIORITY JOURNAL; COMBINATION DRUG THERAPY; GENETICS; HEPATITIS B VIRUS; IMMUNOLOGY;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; RECOMBINANT PROTEINS;

EID: 84964389074     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.12.047     Document Type: Letter

References (4)

1. P. Marcellin, and et al. Gastroenterology 150 2016 134 144
2. H.L. Janssen Lancet 365 2005 123 129
3. G.K. Lau N Engl J Med 352 2005 2682 2695
4. M.J. Sonneveld Hepatology 52 2010 1251 1257